Patent Publication Number: US-2023146808-A1

Title: Injection device storage container

Description:
CROSS REFERENCE TO RELATED APPLICATIONS 
     The present application is the national stage entry of International Patent Application No. PCT/EP2021/058753, filed on Apr. 1, 2021, and claims priority to Application No. EP 20315114.7, filed on Apr. 3, 2020, the disclosures of which are incorporated herein by reference. 
    
    
     TECHNICAL FIELD 
     The present disclosure relates to an injection device storage container for storing one or more injection devices, for example in a refrigerator. 
     BACKGROUND 
     Patients suffering chronic disease require regular treatment with medicaments, e.g., on the basis of a predefined schedule. Particular medicaments require refrigerated storage, and are often stored refrigerated in a household refrigerator, also known as a fridge. In a home treatment environment, the patient stores the medicament in their own refrigerator and administers a predefined dose as required. Hence, the medicament is typically provided in a secondary packaging for convenient placement and storage in the household refrigerator. However, the medicament must be stored together with other items that require constant refrigeration, such as foodstuffs and beverages. 
     Depending on the dosage form of the medicament, the secondary packaging containing the medicament may store a primary packed medicament itself, or may store one or more different kinds of drug delivery devices. For instance, the medicament may be provided in a pre-filled syringe or pen-type injector. 
     There is a desire to improve the storage of injection devices, for example in a refrigerator. 
     SUMMARY 
     It is an aspect of the present disclosure to provide an injection device storage container for storing a plurality of injection devices. 
     According to the present disclosure, there is provided an injection device storage container comprising a case configured to contain at least one injection device for delivering a medicament; and a hanger arrangement coupled to the case and configured to suspend the case from a supporting wall; wherein the case comprises an upper panel having an opening formed therein through which the at least one injection device can be dispensed, and wherein the opening is arranged such that, when the case is suspended from the supporting wall, the at least one injection device is dispensed in a horizontal orientation through the opening. 
     The opening may be dimensioned so that only one injection device of the at least one injection devices can be dispensed through the opening at a time. 
     The injection device storage container may further comprise a guiding arrangement located within the case, wherein the guiding arrangement defines a path along which the at least one injection device can be guided towards the opening. 
     The guiding arrangement may comprise a conduit through which the at least one injection device can move. 
     The guiding arrangement may comprise a sloping lower guide surface, wherein the lower guide surface slopes upwards towards the opening in the upper panel of the case. 
     The injection device storage container may further comprising a propulsion mechanism configured to propel the at least one injection device contained in the case towards the opening. 
     The propulsion mechanism may comprise a resilient member configured to apply a force to the at least one injection device to move it towards the opening. 
     The injection device storage container may further comprise a restraining member arranged adjacent the opening to inhibit removal of the at least one injection device from the opening. 
     The hanger arrangement may comprise a hook configured to hook over a top edge of the supporting wall. 
     The injection device storage container may further comprise a display located on the hook, the display configured to display information to a user indicative of a condition of the injection device storage container or a condition of one or more injection devices contained within the case. 
     The display may be configured to display at least one of a temperature of the injection device storage container, a number of injection devices contained within the case, or an indication of a length of time until an injection is due. 
     The injection device storage container may further comprise a cold pack arranged within the case to moderate an internal temperature of the case. 
     The hanger arrangement may be integrally formed with the case. 
     According to the present disclosure, there is also provided a system comprising an injection device storage container as disclosed herein and at least one injection device contained within the injection device storage container. 
     The at least one injection device may comprise a container containing a medicament. 
    
    
     
       BRIEF DESCRIPTION OF THE FIGURES 
       Embodiments of the invention will now be described, by way of example only, with reference to the accompanying drawings, in which: 
         FIG.  1 A  is a schematic side view of an injection device suitable for storage in the injection device storage container of the present disclosure; 
         FIG.  1 B  is a schematic side view of the injection device of  FIG.  1 A , with the cap removed from the housing; 
         FIG.  2    is an isometric view of an injection device storage container according to embodiments of the present disclosure; 
         FIG.  3    is an isometric view of the injection device storage container of  FIG.  2    when attached to the wall of a refrigerator door shelf; 
         FIG.  4    is an isometric view of the a refrigerator having the injection device storage container of  FIG.  2    attached to the wall of a refrigerator door shelf; 
         FIG.  5    is a schematic side view of the injection device storage container of  FIG.  2   . 
     
    
    
     DETAILED DESCRIPTION 
     The present disclosure provides an injection device storage container configured to contain and store at least one injection device for delivering a medicament. An injection device is an example of a drug delivery device and may be a pen-injector, an auto-injector or the like. The injection device storage container may be stored in a household refrigerator, also known as a fridge. 
     The patient may receive the injection device storage container in an empty condition. When the patient is supplied with one or more injection devices they can be loaded into the injection device storage container. The injection device storage container may be placed in the refrigerator until a scheduled dosing time is due. 
     The injection device storage container may include a hanger arrangement to allow a patient to locate the injection device storage container in various positions in their refrigerator. For example, the injection device storage container may be located for convenient access to make it easier for a patient to be reminded that an injection is due. Depending on the patient&#39;s needs, the storage container may be positioned discreetly in the refrigerator (e.g., to keep the storage container from children), or positioned prominently within the refrigerator to serve as a constant reminder when they open their refrigerator door. The injection device storage container may be conveniently positioned out of the way of food in the refrigerator, in an accessible position. The storage container may also be moved if the patient desires, or temporarily removed for periodic cleaning. Various storage container embodiments are described below. 
     A drug delivery device, as described herein, may be configured to inject a medicament into a patient. For example, delivery could be sub-cutaneous, intra-muscular, or intravenous. Such a device could be operated by a patient or care-giver, such as a nurse or physician, and can include various types of safety syringe, pen-injector, or auto-injector. The device can include a cartridge-based system that requires piercing a sealed ampule before use. Volumes of medicament delivered with these various devices can range from about 0.5 ml to about 3 ml. Another device can include a large volume device (“LVD”) or patch pump, configured to adhere to a patient&#39;s skin for a period of time (e.g., about 5, 15, 30, 60, or 120 minutes) to deliver a “large” volume of medicament (typically about 2 ml to about 10 ml). Yet another device may comprise a pre-filled syringe within a housing of the device. The syringe may be fixed within the housing or may be moveable within the housing, for example from a retracted position to an operation extended position. 
     In combination with a specific medicament, the presently described devices may also be customized in order to operate within required specifications. For example, the device may be customized to inject a medicament within a certain time period (e.g., about 3 to about 20 seconds for auto-injectors, and about 10 minutes to about 60 minutes for an LVD). Other specifications can include a low or minimal level of discomfort, or to certain conditions related to human factors, shelf-life, expiry, biocompatibility, environmental considerations, etc. Such variations can arise due to various factors, such as, for example, a drug ranging in viscosity from about 3 cP to about 50 cP. Consequently, a drug delivery device will often include a hollow needle ranging from about 25 to about 31 Gauge in size. Common sizes are 17 and 29 Gauge. 
     The delivery devices described herein can also include one or more automated functions. For example, one or more of combining the needle and cartridge, needle insertion, medicament injection, and needle retraction can be automated. Energy for one or more automation steps can be provided by one or more energy sources. Energy sources can include, for example, mechanical, pneumatic, chemical, or electrical energy. For example, mechanical energy sources can include springs, levers, elastomers, or other mechanical mechanisms to store or release energy. One or more energy sources can be combined into a single device. Devices can further include gears, valves, or other mechanisms to convert energy into movement of one or more components of a device. 
     The one or more automated functions of an auto-injector may each be activated via an activation mechanism. Such an activation mechanism can include an actuator, for example, one or more of a button, a lever, a needle sleeve, or other activation component. Activation of an automated function may be a one-step or multi-step process. That is, a user may need to activate one or more activation components in order to cause the automated function. For example, in a one-step process, a user may depress a needle sleeve against their body in order to cause injection of a medicament. Other devices may require a multi-step activation of an automated function. For example, a user may be required to depress a button and retract a needle shield in order to cause injection. 
     In addition, activation of one automated function may activate one or more subsequent automated functions, thereby forming an activation sequence. For example, activation of a first automated function may activate at least two of combining the needle and cartridge, needle insertion, medicament injection, and needle retraction. Some devices may also require a specific sequence of steps to cause the one or more automated functions to occur. Other devices may operate with a sequence of independent steps. 
     Some delivery devices can include one or more functions of a safety syringe, pen-injector, or auto-injector. For example, a delivery device could include a mechanical energy source configured to automatically inject a medicament (as typically found in an auto-injector) and a dose setting mechanism (as typically found in a pen-injector). 
     An exemplary drug delivery device  10 , also known as an injection device, suitable for being stored in the injection device storage container of the present disclosure is shown in  FIGS.  1 A and  1 B . Device  10 , as described above, is configured to inject a medicament into a patient&#39;s body. Device  10  includes a housing  11  which typically contains a cartridge or pre-filled syringe that defines a reservoir containing the medicament to be injected, and the components required to facilitate one or more steps of the delivery process. 
     The device  10  can also include a cap  12  that can be detachably mounted to the housing  11 . Typically, a user must remove cap  12  from housing  11  before device  10  can be operated. 
     As shown, housing  11  is substantially cylindrical and has a substantially constant diameter along the longitudinal axis A-A. The housing  11  has a distal region D and a proximal region P. The term “distal” refers to a location that is relatively closer to a site of injection, and the term “proximal” refers to a location that is relatively further away from the injection site. 
     Device  10  can also include a needle sleeve  19  coupled to housing  11  to permit movement of sleeve  19  relative to housing  11 . For example, sleeve  19  can move in a longitudinal direction parallel to longitudinal axis A-A. Specifically, movement of sleeve  19  in a proximal direction can permit a needle  17  to extend from distal region D of housing  11 . 
     Insertion of needle  17  can occur via several mechanisms. For example, needle  17  may be fixedly located relative to housing  11  and initially be located within an extended needle sleeve  19 . Proximal movement of sleeve  19  by placing a distal end of sleeve  19  against a patient&#39;s body and moving housing  11  in a distal direction will uncover the distal end of needle  17 . Such relative movement allows the distal end of needle  17  to extend into the patient&#39;s body. Such insertion is termed “manual” insertion as needle  17  is manually inserted via the patient&#39;s manual movement of housing  11  relative to sleeve  19 . 
     Another form of insertion is “automated”, whereby needle  17  moves relative to housing  11 . Such insertion can be triggered by movement of sleeve  19  or by another form of activation, such as, for example, a button  13 . As shown in  FIGS.  1 A and  1 B , button  13  is located at a proximal end of housing  11 . However, in other embodiments, button  13  could be located on a side of housing  11 . 
     Other manual or automated features can include drug injection or needle retraction, or both. Injection is the process by which a bung or piston  14  is moved from a proximal location to a more distal location within the reservoir of the medicament container  18  in order to force a medicament from the container  18  through needle  17 . In some embodiments, a drive spring (not shown) is under compression before device  10  is activated. A proximal end of the drive spring can be fixed within proximal region P of housing  11 , and a distal end of the drive spring can be configured to apply a compressive force to a proximal surface of piston  14 . Following activation, at least part of the energy stored in the drive spring can be applied to the proximal surface of piston  14 . This compressive force can act on piston  14  to move it in a distal direction. Such distal movement acts to compress the liquid medicament within the container  18 , forcing it out of needle  17 . 
     Following injection, needle  17  can be retracted within sleeve  19  or housing  11 . Retraction can occur when sleeve  19  moves distally as a user removes device  10  from a patient&#39;s body. This can occur as needle  17  remains fixedly located relative to housing  11 . Once a distal end of sleeve  19  has moved past a distal end of needle  17 , and needle  17  is covered, sleeve  19  can be locked. Such locking can include locking any proximal movement of sleeve  19  relative to housing  11 . 
     Another form of needle retraction can occur if needle  17  is moved relative to housing  11 . Such movement can occur if the cartridge  18  within housing  11  is moved in a proximal direction relative to housing  11 . This proximal movement can be achieved by using a retraction spring (not shown), located in distal region D. A compressed retraction spring, when activated, can supply sufficient force to the cartridge  18  to move it in a proximal direction. Following sufficient retraction, any relative movement between needle  17  and housing  11  can be locked with a locking mechanism. In addition, button  13  or other components of device  10  can be locked as required. 
     With reference to  FIGS.  2  to  5   , an injection device storage container  100  according to exemplary embodiments is shown. The injection device storage container  100  is configured to store a plurality of injection devices such as the injection device  10  previously described in relation to  FIGS.  1 A and  1 B . 
       FIG.  2    shows the injection device storage container  100  comprising a case  110 . The case  110  comprises a front wall  130 , a rear wall  141 , and two side walls  142 . The case  110  also has a base  135  and an upper panel  120 , also known as a lid. The upper panel  120  may be removable, or may be permanently attached to the walls  130 ,  141 ,  142 . The upper panel  120  forms the top of the case  110 . 
     The case  110  is configured to hold and store a plurality of injection devices  10 . In particular, the case  110  is configured to contain a plurality of injection devices  10  such as the injection devices  10  of  FIGS.  1 A and  1 B  in a horizontal orientation. This means that the injection devices  10  are orientated such that the longitudinal axis of each injection device  10  is substantially parallel to the base  135  and the upper panel  120  of the case  110 , when the injection device storage container  100  is suspended from a refrigerator shelf wall as discussed later. 
     A width of the case  110 , measured between the two side walls  142 , is sufficient to accommodate the length of an injection device  10  such as the injection device  10  previously described in relation to  FIGS.  1 A and  1 B . The width of the case may be between about 150 mm and about 250 mm. A height of the case  110 , measured between the base  135  and the upper panel  120 , is sufficient to accommodate the width of at least one injection device  10 . The height of the case may be between about 30 mm and about 200 mm. A depth of the case  110 , measured between the front wall  131  and the rear wall  141 , is sufficient to accommodate the width of at least one injection device  10 . The depth of the case may be between about 30 mm and about 180 mm. 
     As shown in  FIG.  2   , the upper panel  120  extends from a top edge of the front wall  131  to a top edge of the rear wall  141 . An opening  122  is located in the upper panel  120  of the case  110 , through which the injection devices  10  stored inside the case  110  may be removed or otherwise dispensed. The injection devices  10  are therefore removed through the top of the case  110 , in a direction substantially away from the ground when the injection device storage container  100  is suspended in a refrigerator. The opening  122  is arranged so that the injection devices  10  are dispensed outside the case  110  in their horizontal orientation—in other words sideways, or tangential to the upper panel  120 —through the opening  122 . 
     An injection device  10  may be dispensed through the opening  122  by a user physically grasping the injection device  10  nearest the opening  122  and removing the injection device  10  from the container  100 . In other examples, the injection device  10  may be automatically dispensed by the injection device storage container  100 , for example by an electromechanical dispensing mechanism. 
     The opening  122  may have a rectangular shape. A width of the opening  122  is sufficient to accommodate the width of an injection device  10 , while a length of the opening  122  is sufficient to accommodate the length of an injection device  10 . The opening  122  may be dimensioned so that only one injection device  10  may be removed at a time. This may assist with patient compliance of an injection regimen. 
     The opening  122  may have a recess portion  123  formed in the upper panel  120  to assist a user in removing an injection device  10  from the case  110 . The recess portion  123  may be dimensioned to receive at least part of a user&#39;s finger to assist the user in grasping the injection device  10  for removal from the case  110 . More than one recess portion  123  may be formed in the opening  122 . For example there may be two recess portions  123 , with one recess portion  123  formed on each opposing side of the opening  122  so that a user may place a finger in each recess portion  123 , either side of the injection device  10 . 
     The case  110  may optionally have one or more restraining members  129  arranged adjacent the opening  122  for inhibiting removal of an injection device  10  from the injection device storage container  100 . The restraining member  129  inhibits removal of an injection device  10  by making it more difficult to remove the injection device  10  than if the restraining member  129  were not present. 
       FIG.  2    shows two restraining members  129 , however there may be more restraining members  129  than this, or fewer. The one or more restraining members  129  are formed as one or more protrusions extending from the upper panel  120 , partially across the opening  122 , to impede removal of an injection device  10  from the opening  122 . The restraining member  129  may protrude between 1 mm and 5 mm into the opening  122  from an edge of the opening  122 , for example. 
     The restraining member  129  may be formed of a resilient or flexible material which allows the restraining member  129  to be deformed upon application of a force on the restraining member  129 . The restraining member  129  may prevent an injection device  10  from being removed from the opening  122  of the case  110  unless a removal force greater than a threshold value is applied to the restraining member  129  via the injection device  10 . 
     The front wall  131 , the rear wall  141 , the two side walls  142 , the base  135  and the upper panel  120  may be formed from an opaque material, for example, an opaque plastic material. In other examples, one or more of the front wall  131 , the rear wall  141 , the two side walls  142 , the base  135  and the upper panel  120  may wholly or in part be formed from a transparent material, or formed from a translucent or frosted material, for example, a clear plastic material with a frosted coating or a treated surface. A portion of the upper panel  120  may be transparent so that a user may view the interior of the case  110  to identify the number of injection devices  10  contained within the case  110 . 
     The injection device storage container  100  further comprises a hanger arrangement  292 . The hanger arrangement  292  is coupled to the case  110  and is configured to hang the injection device storage container  100  from a supporting object such as a wall of a refrigerator shelf. 
     The hanger arrangement  292  comprises an extending part  293  and a hook  295 . The extending part  293  is arranged to extend away from the case  110 , in particular away from the upper panel  120  of the case  110 . The hook  295  is arranged at an end of the extending part  293  furthest from the case  110 . The hook  295  is configured to fit over a supporting body. The case  110  hangs directly below the hook  295  at a lower end of the extending part  293 . 
     The extending part  293  may extend from the case  110  substantially in the same plane as the front wall  130 . When the hanger arrangement  292  is hanging from a supporting object, the extending part  293  extends upwards. 
     The extending part  293  is a rectangular shape. The length of the extending part  293 , which is measured along the top edge of the front wall  130 , may be between about 50 mm and about 200 mm. The height of the extending part  293  may be between about 1 mm and about 50 mm. 
     The extending part  293  of the hanger arrangement  292  may be attached to the case  110  by welding or bonding, or another suitable means of coupling. Alternatively, the hanger arrangement  292  and case  110  may be formed from a single piece, such as by casting or machining. For example, the hanger arrangement  292  and at least one of the upper panel  120  and the front wall  130  may be integrally formed, such as through an injection moulding process. 
     The hook  295  extends from an end of the extending part  293  which is furthest from the case  110 . The hook  295  is configured to engage with a supporting object such as a wall of a refrigerator door shelf. The hook  295  is shaped to fit over the supporting object such that the extending part  293  of the hanger arrangement  292  hangs beneath a top edge of the supporting object. 
     With respect to the extending part  293 , the hook  295  extends out of the plane of the extending part  293  in a direction away from the front wall  130 . That is, the hook  295  is disposed away from the case  110 . The hanger arrangement  292  is configured to support the case  110  directly below the hook  295 , when the hook  295  is hanging from a supporting object. 
     The hook  295  comprises a first part  295   a  and a second part  295   b.  The first part  295   a  extends from the end of the extending part  293 . The first part  295   a  extends perpendicular to the extending part  293 , in a forward direction from the extending part  293 . That is, the first part  295   a  extends in a direction away from the case  110 , in a direction perpendicular to the plane of the front wall  130 . 
     The second part  295   b  extends from an end of the first part  295   a  which is furthest from the extending part  293 . The second part  295   b  extends perpendicular to the first part  295   a.  The second part  295   b  extends in a sideways direction from the first part  295   a . That is, the second part  295   b  extends along an axis which is parallel to the extending part  293 , and substantially parallel to the front wall  130 . 
     The length of the first part  295   a,  when measured in a direction away from the front wall  130  of the case  110 , may be between about 5 mm and about 20 mm. The length of the second part  295   b,  when measured extending from the first part  295   b  may be between about 15 mm and about 50 mm. The hanger arrangement  292  may be deflected to form the hook  295 . The hook  295  may be formed having square corners where deflected, as shown in  FIG.  2   . Alternatively, the hook  295  may be rounded. The hanger arrangement  292  may be bent or folded to form the hook  295 . Alternatively, a second piece of material may be attached to the extending part  293  at a right angle to form the first part  295   a,  and a third piece of material may be attached to the first part  295   a  to form the second park  295   b.    
     In some examples, the extending part  293  may not be present. For example, the hook  295  may be coupled to the case  110  without an extending part  293  between the case  110  and the hook  295 . In such an example, the first part  295   a  of the hook  295  may be coupled to, and extend from, the front wall  130 . The first part  295   a  extends in a forward direction from the front wall  130 . That is, the first part  295   a  extends in a direction away from the case  110 . 
     The hanger arrangement  292  allows the case  110  of the injection device storage container  100  to be suspended inside a household refrigerator. In particular, the hanger arrangement  292  can be hung from a door shelf of the refrigerator. 
     The injection device storage container  100  may also comprise a display  161 . The display  161  may be any form of display  161  suitable for conveying information to a patient, for example an electronic display such as an LCD display or one or more LEDs. The display  161  may be configured to display information to a user related to a condition of the injection device storage container  100  and/or a condition of one or more injection devices  10  contained within the case  110 . For example, the display may be configured to display information representing a temperature of the injection device storage container  100  or a number of injection devices  10  contained within the case  110 . In other examples the information may represent a time, for example an indication of a length of time until an injection is due, or a length of time since an injection device was removed from the case  110 . 
     The display  161  is arranged on the hook  190 , in particular on a front surface  298  of the second part  295   b  of the hook. The front surface  290  is on the opposite side of the hook  190  to the extending part  293  and case  110 , and faces away from the front wall  130  of the case. Positioning the display on the front surface  298  of the hook  190  allows a patient to easily view displayed information regarding a condition of the injection device storage container  100  and/or injection devices  10  contained within. 
       FIGS.  3  and  4    show the injection device storage container  100  of  FIG.  2    when located in a typical refrigerator door shelf  500  of a refrigerator  600 . A typical refrigerator door shelf  500  is a tray shape having a base and four vertical walls, namely a front wall  530 , a rear wall  541  and a pair of side walls  542 . The tray is mounted on horizontal rails formed in the internal face of the refrigerator door and can be slidably removed in a direction perpendicular to the internal face of the refrigerator door. 
     The hook  295  can be placed over the front wall  530  of the tray which faces away from the internal face of the refrigerator door when the tray is mounted thereon. The second part  295   b  of the hook is located adjacent the front surface of the front wall  530  of the refrigerator door shelf  500 , while the front wall  130  of the case  110  is located adjacent the rear surface of the front wall  530  of the refrigerator door shelf  500 . The injection device storage container  100  is suspended within the refrigerator door shelf  500 , in the space defined by the four vertical walls and base. 
     By providing a hanger arrangement  292  for suspending the injection device storage container  100  within the refrigerator door shelf  500 , the injection device storage container  100  can be placed in a prominent position in the refrigerator door shelf  500  while still being isolated from foodstuffs. Suspending the injection device storage container  100  may allow other items to be stored in the refrigerator  600  in a space created underneath the base  135  of the storage container  100 , thereby better utilising the limited space of the refrigerator  600 . 
     The injection device storage container  100  can be located in a prominent position on the refrigerator door. The injection device storage container  100  is located away from food and the like in the refrigerator. The injection device storage container  100  is unlikely to be covered or knocked in this location. 
     When the injection device storage container  100  is hung from the front wall  530  of the refrigerator door shelf  500  using the hanger arrangement  292 , the front wall  130 , rear wall  141 , and two side walls  142  of the injection device storage container  100  are substantially parallel to the walls of the refrigerator door shelf  500 . The base  135  and the upper panel  120  of the case  110  are substantially parallel to the base of the refrigerator door shelf  500 . The front wall  130  faces the patient when the refrigerator door is opened. The patient can see the upper panel  120  of the case  110  and the opening  122  when viewing the refrigerator door shelf  500  from above. 
     As can be seen in  FIG.  3   , the injection device storage container  100  is substantially contained within the refrigerator door shelf, reducing visibility of the injection device storage container  100  and ensuring the injection device storage container is out of the way of the inside of the refrigerator. However the presence of the hanger arrangement  292  at the front wall of the refrigerator door shelf allows for simple attachment and detachment of the injection device storage container from the refrigerator door shelf. The hook  190  of the hanger arrangement  292  being visible from the front of the refrigerator door shelf front wall allows a patiently to quickly and easily identify the location of the injection device storage container  100  within the refrigerator, which may be particularly useful where the refrigerator door shelves  500   a,    500   b,    500   c,    500   d  are opaque, or where the injection device storage container  100  is located in one of the upper refrigerator door shelves  500   a  that would be difficult for a patient to otherwise see the contents of. 
     The location of the display  161  on the hook  295  means that it is clearly visible from outside the refrigerator door shelf, allowing a patient to easily be presented with information regarding a condition of the injection device storage container and/or injection devices  10  it contains. The user may therefore be able to suspend the injection device storage container  100  from the uppermost refrigerator door shelf  500   a  of the refrigerator  600  and still view the displayed information. 
     It can be seen in  FIG.  3    that the location of the opening  122  at the upper panel  120  of the case  110  allows a patient to have easy access to the injection devices  100  contained in the injection device storage container  100 . The injection devices  10  are arranged horizontally in the injection device storage container  100  so that the longitudinal axis of each injection device  10  is parallel to the plane of the front wall  130 . Storing and dispensing the injection devices  10  in a horizontal orientation allows for easy retrieval of an injection device  10  by a patient, for example those patients with reduced dexterity. 
       FIG.  5    shows a schematic cross section of the injection device storage container  100  of  FIG.  3    when viewed from the side. 
     An injection device guiding arrangement  400  is located within the case  110 . The guiding arrangement  400  is configured to guide the injection devices  10   a - f  contained within the case  110  towards the opening  122 , so that they can be dispensed. The guiding arrangement  400  defines a path P along which the plurality of injection devices  10   a - f  can be guided towards the opening  122 . 
     The guiding arrangement  400  is arranged to contain each of the injection devices  10  in the horizontal orientation described previously. As can be seen in  FIG.  5   , the injection devices  10   a - f  are arranged horizontally by the guiding arrangement  400  such that the longitudinal axis of each injection device  10   a - f  is substantially parallel to the plane of the upper panel  120 , and to the front wall  130 . The longitudinal axis of each injection device  10   a - f  shown in  FIG.  5    extends perpendicular to the page. 
     The guiding arrangement  400  may be formed as a conduit through which the injection devices  10   a - f  may move towards the opening  122 , while remaining in the horizontal orientation. For example, the injection devices  10   a - f  could slide towards the opening  122  or roll towards the opening  122 . 
       FIG.  5    shows the guiding arrangement  400  comprising a sloping lower guide surface  420 , wherein the lower guide surface  420  slopes upwards towards the opening  122  in the upper panel  120  of the case  110 . An injection device  10   a - f  moving along the path P formed by the guiding arrangement  400  moves up the sloping lower guide surface  420  towards the opening  122 . The lower guide surface  420  may comprise a ramp, or may comprise one or more rails along which the injection devices  10  may slide or roll. 
     The guiding arrangement  400  may also comprise an upper guide surface  430  arranged above the lower guide surface  420 , that is nearer the upper panel  120  of the case  110 . The upper guide surface  430  and lower guide surface  420  are separated by a predefined distance in order to form a passage  410  through which the injection devices  10   a - f  can be guided along the path P. 
     The distance between the upper guide surface  430  and lower guide surface  420  may be substantially constant along the path P formed between upper guide surface  430  and lower guide surface  420  so that the passage has a constant height. The distance between the upper guide surface  430  and lower guide surface  420  is at least large enough to accommodate the width of an injection device  10 . The distance between the upper guide surface  430  and lower guide surface  420  may substantially correspond to the width of a single injection device  10  so that the injection devices  10   a - f  are tightly constrained and guided by the upper guide surface  430  and lower guide surface  420 . 
     The injection device storage container  100  may have a propulsion mechanism  800  located within the case  110 . The propulsion mechanism  800  is arranged to propel the injection devices  10  towards the opening  122  so that they can be dispensed. As discussed previously, the opening  122  through which the injection devices  10  are dispensed is formed in the upper panel  120  of the case  110 . The propulsion mechanism  800  can therefore assist in transporting injection devices  10   a - f  from inside the lower part of the case  110  towards the upper part of the case  11 , along the path P formed by the guiding arrangement  400 , so that they can be dispensed from the top of the case  110 . 
       FIG.  5    shows the propulsion mechanism  400  comprising a resilient member  810  such as a spring. One end of the resilient member  810  is coupled to the case  110 , for example the rear wall  141  of the case  110 . The other end of the resilient member  810  is coupled to a contact member  820 . When one or more injection devices  10   a - f  are contained within the case  110 , the contact member  820  is arranged to be in contact with at least one of the injection devices  10   a - f.    FIG.  5    shows the contact member  820  in contact with the rearmost injection device  10   f.    
     In some examples, no contact member  820  is present and the resilient member  810  contacts one or more of the injection devices  10  directly. 
     The resilient member  810  exerts a force on the injection device  10   f  via the contact member  820 , urging the injection device  10   f  towards the opening  122  so that it can be dispensed. Where the case  110  contains a plurality of injection devices  10   a - f,  as shown in  FIG.  5   , the force applied by the resilient member  810  may be applied to all of the injection devices  10   a - f,  causing them each to be biased towards the opening  122 . 
     Alternatively, or additionally, other suitable forms of propulsion mechanism  400  may be used such as an electromechanical assembly. 
       FIG.  5    shows a restraining member  129  located adjacent the opening  122  of the case  110 . The restraining member  129  may counterbalance the force applied to the injection devices  10   a - f  by the propulsion mechanism  800 . The restraining member  129  may therefore inhibit the injection devices  10  from being fully dispensed out of the opening  122  by the propulsion mechanism  800 , without patient intervention. 
       FIG.  5    also shows the injection device storage container  100  comprising a cold pack  700 . The cold pack  700  may alternatively be known as an ice pack, however it should be noted that the term ice pack does not necessarily mean that the ice pack is at a temperature below the freezing point of water. The cold pack  700  is located within the case  110 . The cold pack  700  moderates the temperature of the injection device storage container  100  and the injection devices  10   a - f  held inside. The cold pack  700  may comprise a phase change material (PCM). 
     The cold pack  700  is formed from a material that is slow to change temperature. When the injection device storage container  100  is located inside a closed refrigerator  600 , the cold pack  700  reaches an equilibrium temperature with the internal temperature of the refrigerator  600 . When the refrigerator door is opened, the immediate environment around the injection device storage container  100  may begin to increase in temperature due to exposure to warmer air outside the refrigerator  600 . However, the cold pack  700  within the case  110  resists the increase in temperature, moderating the temperature of the inside of the case  110  and the injection devices  10   a - f  held within, keeping them cold. The cold pack  700  may be of particular use where the injection device storage container  100  is completely removed from the refrigerator  600 , for example when the injection device storage container  100  is portable and is being transported by a patient. 
     One or more of the front wall  131 , the rear wall  141 , the two side walls  142 , the base  135  and the upper panel  120  of the case  100  may be made from a thermally insulating material. This can help shield the injection devices  10  contained within the injection device storage container  100  from temperature variations outside the case  110 . The thermally insulating material may keep the injection devices  10  colder for a longer period of time compared to use of a non-thermally insulting material. 
     Relative orientations disclosed herein are to be interpreted from the viewpoint of when the injection device storage container  100  is suspended from a supporting wall of a refrigerator using the hanger arrangement  292 , as shown in  FIGS.  3 ,  4  and  5   . For example, when the injection device storage container  100  is suspended from the front wall  530  of a refrigerator door shelf  500  using then hanger arrangement  292 , the front wall  130  of the case  110  is the wall nearest the front wall  530  of the refrigerator door shelf  530 , the rear wall  141  of the case  110  is the wall furthest the front wall  530  of the refrigerator door shelf  530 , the base  135  of the injection device storage container  100  forms the surface nearest the base of the refrigerator door shelf  500 , and the upper panel  120  forms the upper surface of the case  110 , opposite and above the base  135  relative to the ground. 
     With respect to the injection devices  10  described herein, the term ‘horizontal orientation’ means an orientation in which the longitudinal axis of the injection device  10  is parallel to the ground, and parallel to the base  135  of the case  110  and refrigerator door shelf  500  when the injection device storage container  100  is suspended from the front wall  530  of the refrigerator door shelf  500 . 
     The injector devices described herein are configured to receive either a cartridge of medicament or a syringe pre-filled with a medicament. Herein, the term “medicament container” is intended to encompass both a cartridge of medicament and a pre-filled syringe. 
     The terms “drug” or “medicament” are used herein to describe one or more pharmaceutically active compounds. As described below, a drug or medicament can include at least one small or large molecule, or combinations thereof, in various types of formulations, for the treatment of one or more diseases. Exemplary pharmaceutically active compounds may include small molecules; polypeptides, peptides and proteins (e.g., hormones, growth factors, antibodies, antibody fragments, and enzymes); carbohydrates and polysaccharides; and nucleic acids, double or single stranded DNA (including naked and cDNA), RNA, antisense nucleic acids such as antisense DNA and RNA, small interfering RNA (siRNA), ribozymes, genes, and oligonucleotides. Nucleic acids may be incorporated into molecular delivery systems such as vectors, plasmids, or liposomes. Mixtures of one or more of these drugs are also contemplated. 
     The term “drug delivery device” shall encompass any type of device or system configured to dispense a drug into a human or animal body. Without limitation, a drug delivery device may be an injector device (e.g., syringe, pen injector, auto injector, large-volume device, pump, perfusion system, or other device configured for intraocular, subcutaneous, intramuscular, or intravascular delivery), skin patch (e.g., osmotic, chemical, micro-needle), inhaler (e.g., nasal or pulmonary), implantable (e.g., coated stent, capsule), or feeding systems for the gastro-intestinal tract. The presently described drugs may be particularly useful with injector devices that include a needle, e.g., a small gauge needle. 
     The drug or medicament may be contained in a primary package or “drug container” adapted for use with a drug delivery device. The drug container may be, e.g., a cartridge, syringe, reservoir, or other vessel configured to provide a suitable chamber for storage (e.g., short- or long-term storage) of one or more pharmaceutically active compounds. For example, in some instances, the chamber may be designed to store a drug for at least one day (e.g., 1 to at least 30 days). In some instances, the chamber may be designed to store a drug for about 1 month to about 2 years. Storage may occur at room temperature (e.g., about 20° C.), or refrigerated temperatures (e.g., from about −4° C. to about 4° C.). In some instances, the drug container may be or may include a dual-chamber cartridge configured to store two or more components of a drug formulation (e.g., a drug and a diluent, or two different types of drugs) separately, one in each chamber. In such instances, the two chambers of the dual-chamber cartridge may be configured to allow mixing between the two or more components of the drug or medicament prior to and/or during dispensing into the human or animal body. For example, the two chambers may be configured such that they are in fluid communication with each other (e.g., by way of a conduit between the two chambers) and allow mixing of the two components when desired by a user prior to dispensing. Alternatively or in addition, the two chambers may be configured to allow mixing as the components are being dispensed into the human or animal body. 
     The drug delivery devices and drugs described herein can be used for the treatment and/or prophylaxis of many different types of disorders. Exemplary disorders include, e.g., diabetes mellitus or complications associated with diabetes mellitus such as diabetic retinopathy, thromboembolism disorders such as deep vein or pulmonary thromboembolism. Further exemplary disorders are acute coronary syndrome (ACS), angina, myocardial infarction, cancer, macular degeneration, inflammation, hay fever, atherosclerosis and/or rheumatoid arthritis. 
     Exemplary drugs for the treatment and/or prophylaxis of diabetes mellitus or complications associated with diabetes mellitus include an insulin, e.g., human insulin, or a human insulin analogue or derivative, a glucagon-like peptide (GLP-1), GLP-1 analogues or GLP-1 receptor agonists, or an analogue or derivative thereof, a dipeptidyl peptidase-4 (DPP4) inhibitor, or a pharmaceutically acceptable salt or solvate thereof, or any mixture thereof. As used herein, the term “derivative” refers to any substance which is sufficiently structurally similar to the original substance so as to have substantially similar functionality or activity (e.g., therapeutic effectiveness). 
     Exemplary insulin analogues are Gly(A21), Arg(B31), Arg(B32) human insulin (insulin glargine); Lys(B3), Glu(B29) human insulin; Lys(B28), Pro(B29) human insulin; Asp(B28) human insulin; human insulin, wherein proline in position B28 is replaced by Asp, Lys, Leu, Val or Ala and wherein in position B29 Lys may be replaced by Pro; Ala(B26) human insulin; Des(B28-B30) human insulin; Des(B27) human insulin and Des(B30) human insulin. 
     Exemplary insulin derivatives are, for example, B29-N-myristoyl-des(B30) human insulin; B29-N-palmitoyl-des(B30) human insulin; B29-N-myristoyl human insulin; B29-N-palmitoyl human insulin; B28-N-myristoyl LysB28ProB29 human insulin; B28-N-palmitoyl-LysB28ProB29 human insulin; B30-N-myristoyl-ThrB29LysB30 human insulin; B30-N-palmitoyl-ThrB29LysB30 human insulin; B29-N-(N-palmitoyl-gamma-glutamyl)-des(B30) human insulin; B29-N-(N-lithocholyl-gamma-glutamyl)-des(B30) human insulin; B29-N-(ω-carboxyheptadecanoyl)-des(B30) human insulin and B29-N-(ω-carboxyhepta¬decanoyl) human insulin. Exemplary GLP-1, GLP-1 analogues and GLP-1 receptor agonists are, for example: Lixisenatide/AVE0010/ZP10/Lyxumia, Exenatide/Exendin-4/Byetta/Bydureon/ITCA 650/AC-2993 (a 39 amino acid peptide which is produced by the salivary glands of the Gila monster), Liraglutide/Victoza, Semaglutide, Taspoglutide, Syncria/Albiglutide, Dulaglutide, rExendin-4, CJC-1134-PC, PB-1023, TTP-054, Langlenatide/HM-11260C, CM-3, GLP-1 Eligen, ORMD-0901, NN-9924, NN-9926, NN-9927, Nodexen, Viador-GLP-1, CVX-096, ZYOG-1, ZYD-1, GSK-2374697, DA-3091, MAR-701, MAR709, ZP-2929, ZP-3022, TT-401, BHM-034. MOD-6030, CAM-2036, DA-15864, ARI-2651, ARI-2255, Exenatide-XTEN and Glucagon-Xten. 
     An exemplary oligonucleotide is, for example: mipomersen/Kynamro, a cholesterol-reducing antisense therapeutic for the treatment of familial hypercholesterolemia. 
     Exemplary DPP4 inhibitors are Vildagliptin, Sitagliptin, Denagliptin, Saxagliptin, Berberine. 
     Exemplary hormones include hypophysis hormones or hypothalamus hormones or regulatory active peptides and their antagonists, such as Gonadotropine (Follitropin, Lutropin, Choriongonadotropin, Menotropin), Somatropine (Somatropin), Desmopressin, Terlipressin, Gonadorelin, Triptorelin, Leuprorelin, Buserelin, Nafarelin, and Goserelin. 
     Exemplary polysaccharides include a glucosaminoglycane, a hyaluronic acid, a heparin, a low molecular weight heparin or an ultra-low molecular weight heparin or a derivative thereof, or a sulphated polysaccharide, e.g. a poly-sulphated form of the above-mentioned polysaccharides, and/or a pharmaceutically acceptable salt thereof. An example of a pharmaceutically acceptable salt of a poly-sulphated low molecular weight heparin is enoxaparin sodium. An example of a hyaluronic acid derivative is Hylan G-F 20/Synvisc, a sodium hyaluronate. 
     The term “antibody”, as used herein, refers to an immunoglobulin molecule or an antigen-binding portion thereof. Examples of antigen-binding portions of immunoglobulin molecules include F(ab) and F(ab′)2 fragments, which retain the ability to bind antigen. The antibody can be polyclonal, monoclonal, recombinant, chimeric, de-immunized or humanized, fully human, non-human, (e.g., murine), or single chain antibody. In some embodiments, the antibody has effector function and can fix complement. In some embodiments, the antibody has reduced or no ability to bind an Fc receptor. For example, the antibody can be an isotype or subtype, an antibody fragment or mutant, which does not support binding to an Fc receptor, e.g., it has a mutagenized or deleted Fc receptor binding region. 
     The terms “fragment” or “antibody fragment” refer to a polypeptide derived from an antibody polypeptide molecule (e.g., an antibody heavy and/or light chain polypeptide) that does not comprise a full-length antibody polypeptide, but that still comprises at least a portion of a full-length antibody polypeptide that is capable of binding to an antigen. Antibody fragments can comprise a cleaved portion of a full length antibody polypeptide, although the term is not limited to such cleaved fragments. Antibody fragments that are useful in the present invention include, for example, Fab fragments, F(ab′)2 fragments, scFv (single-chain Fv) fragments, linear antibodies, monospecific or multispecific antibody fragments such as bispecific, trispecific, and multispecific antibodies (e.g., diabodies, triabodies, tetrabodies), minibodies, chelating recombinant antibodies, tribodies or bibodies, intrabodies, nanobodies, small modular immunopharmaceuticals (SMIP), binding-domain immunoglobulin fusion proteins, camelized antibodies, and VHH containing antibodies. Additional examples of antigen-binding antibody fragments are known in the art. 
     The terms “Complementarity-determining region” or “CDR” refer to short polypeptide sequences within the variable region of both heavy and light chain polypeptides that are primarily responsible for mediating specific antigen recognition. The term “framework region” refers to amino acid sequences within the variable region of both heavy and light chain polypeptides that are not CDR sequences, and are primarily responsible for maintaining correct positioning of the CDR sequences to permit antigen binding. Although the framework regions themselves typically do not directly participate in antigen binding, as is known in the art, certain residues within the framework regions of certain antibodies can directly participate in antigen binding or can affect the ability of one or more amino acids in CDRs to interact with antigen. 
     Exemplary antibodies are anti PCSK-9 mAb (e.g., Alirocumab), anti IL-6 mAb (e.g., Sarilumab), and anti IL-4 mAb (e.g., Dupilumab). 
     The compounds described herein may be used in pharmaceutical formulations comprising (a) the compound(s) or pharmaceutically acceptable salts thereof, and (b) a pharmaceutically acceptable carrier. The compounds may also be used in pharmaceutical formulations that include one or more other active pharmaceutical ingredients or in pharmaceutical formulations in which the present compound or a pharmaceutically acceptable salt thereof is the only active ingredient. Accordingly, the pharmaceutical formulations of the present disclosure encompass any formulation made by admixing a compound described herein and a pharmaceutically acceptable carrier. 
     Pharmaceutically acceptable salts of any drug described herein are also contemplated for use in drug delivery devices. Pharmaceutically acceptable salts are for example acid addition salts and basic salts. Acid addition salts are e.g. HCl or HBr salts. Basic salts are e.g. salts having a cation selected from an alkali or alkaline earth metal, e.g. Na+, or K+, or Ca2+, or an ammonium ion N+(R1)(R2)(R3)(R4), wherein R1 to R4 independently of each other mean: hydrogen, an optionally substituted C1 C6-alkyl group, an optionally substituted C2-C6-alkenyl group, an optionally substituted C6-C10-aryl group, or an optionally substituted C6-C10-heteroaryl group. Further examples of pharmaceutically acceptable salts are known to those of skill in the arts. 
     Pharmaceutically acceptable solvates are for example hydrates or alkanolates such as methanolates or ethanolates. 
     Those of skill in the art will understand that modifications (additions and/or removals) of various components of the substances, formulations, apparatuses, methods, systems and embodiments described herein may be made without departing from the full scope and spirit of the present invention, which encompass such modifications and any and all equivalents thereof.